Orphazyme A/S announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme A/S to take on the role as CEO of LEO Pharma A/S. Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
999.7 DKK | 0.00% | -1.49% | -24.83% |
03-27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
1st Jan change | Capi. | |
---|---|---|
-24.83% | 5.15M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- ORPHA Stock
- News Orphazyme A/S
- Orphazyme A/S Announces CEO Changes